Interestingly, in a retrospective review following switch to aflibercept of 45 non-responsive eyes initially treated with ranibizumab, baseline SRF predicted shorter recurrence-free treatment interval whereas baseline IRF predicted longer recurrence-free treatment interval at 12 months [19] indicating a complex relationship between fluid, disease activity and treatment intensity in eyes with ongoing anti-VEGF treatment for wet AMD. The gene discussed is VEGFA; the disease is wet macular degeneration.